Characterization of prolactin receptors and their distribution among American and Israeli women with breast cancer: Implications for prediction of hormonal dependency and treatment

M. Ben-David, T. Kadar, J. Wittliff, S. Biran, Andrew V Schally

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A micro-method is reported for the determination and characterization of prolactin (PRL) receptors in human breast cancer specimens using either intact biopsy tissue or the pellet fraction remaining from biopsies previously processed for steroid hormone receptors. Labeled human PRL is used as the ligand. The specific PRL-binding of 307 human breast cancer specimens was evaluated by this micro-method. A significant level of specific PRL-binding (3-25 fmol per mg membrane protein) was detected in 41% of US breast cancer patients and 42% of Israeli patients. Scatchard analyses, performed on pooled membrane fractions with the highest specific PRL-binding revealed one class of receptors having a dissociation constant, K(d) = 4.1 x 10-9, and specific binding capacity, B(max) = 1.3 pmol per mg protein. These preparations were exposed to 3 M MgCl2, which dissociates the endogenous-bound PRL from the hormone-receptor complex and allows the characterization of the 'total' PRL receptors. Two classes of receptors were then revealed. One class of receptors showed highly affinity (K(d1) = 8.1 x 10-10 M) and low capacity (B(max1) = 335 fmol per mg protein), while the other possessed lower affinity (K(d2) = 8.2 x 10-8 M), but a higher capacity (B(max2) = 34.4 pmol per mg proteins). Since PRL facilitates the growth of human breast cancer cell lines, these results indicate that a high proportion of human breast cancers may be PRL dependent. Routine determination of PRL receptors in biopsies of human breast cancer may permit the selection of a better treatment, since it is possible that the reduction in PRL levels could inhibit those tumors which are prolactin dependent.

Original languageEnglish
Pages (from-to)101-109
Number of pages9
JournalBiomedicine and Pharmacotherapy
Volume42
Issue number2
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Prolactin Receptors
Prolactin
Breast Neoplasms
Therapeutics
Biopsy
Hormones
Proteins
Magnesium Chloride
Steroid Receptors
Membrane Proteins
Ligands
Cell Line
Membranes

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{9a2188fccb614c24aff690f7217ac738,
title = "Characterization of prolactin receptors and their distribution among American and Israeli women with breast cancer: Implications for prediction of hormonal dependency and treatment",
abstract = "A micro-method is reported for the determination and characterization of prolactin (PRL) receptors in human breast cancer specimens using either intact biopsy tissue or the pellet fraction remaining from biopsies previously processed for steroid hormone receptors. Labeled human PRL is used as the ligand. The specific PRL-binding of 307 human breast cancer specimens was evaluated by this micro-method. A significant level of specific PRL-binding (3-25 fmol per mg membrane protein) was detected in 41{\%} of US breast cancer patients and 42{\%} of Israeli patients. Scatchard analyses, performed on pooled membrane fractions with the highest specific PRL-binding revealed one class of receptors having a dissociation constant, K(d) = 4.1 x 10-9, and specific binding capacity, B(max) = 1.3 pmol per mg protein. These preparations were exposed to 3 M MgCl2, which dissociates the endogenous-bound PRL from the hormone-receptor complex and allows the characterization of the 'total' PRL receptors. Two classes of receptors were then revealed. One class of receptors showed highly affinity (K(d1) = 8.1 x 10-10 M) and low capacity (B(max1) = 335 fmol per mg protein), while the other possessed lower affinity (K(d2) = 8.2 x 10-8 M), but a higher capacity (B(max2) = 34.4 pmol per mg proteins). Since PRL facilitates the growth of human breast cancer cell lines, these results indicate that a high proportion of human breast cancers may be PRL dependent. Routine determination of PRL receptors in biopsies of human breast cancer may permit the selection of a better treatment, since it is possible that the reduction in PRL levels could inhibit those tumors which are prolactin dependent.",
author = "M. Ben-David and T. Kadar and J. Wittliff and S. Biran and Schally, {Andrew V}",
year = "1988",
month = "1",
day = "1",
language = "English",
volume = "42",
pages = "101--109",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",
number = "2",

}

TY - JOUR

T1 - Characterization of prolactin receptors and their distribution among American and Israeli women with breast cancer

T2 - Implications for prediction of hormonal dependency and treatment

AU - Ben-David, M.

AU - Kadar, T.

AU - Wittliff, J.

AU - Biran, S.

AU - Schally, Andrew V

PY - 1988/1/1

Y1 - 1988/1/1

N2 - A micro-method is reported for the determination and characterization of prolactin (PRL) receptors in human breast cancer specimens using either intact biopsy tissue or the pellet fraction remaining from biopsies previously processed for steroid hormone receptors. Labeled human PRL is used as the ligand. The specific PRL-binding of 307 human breast cancer specimens was evaluated by this micro-method. A significant level of specific PRL-binding (3-25 fmol per mg membrane protein) was detected in 41% of US breast cancer patients and 42% of Israeli patients. Scatchard analyses, performed on pooled membrane fractions with the highest specific PRL-binding revealed one class of receptors having a dissociation constant, K(d) = 4.1 x 10-9, and specific binding capacity, B(max) = 1.3 pmol per mg protein. These preparations were exposed to 3 M MgCl2, which dissociates the endogenous-bound PRL from the hormone-receptor complex and allows the characterization of the 'total' PRL receptors. Two classes of receptors were then revealed. One class of receptors showed highly affinity (K(d1) = 8.1 x 10-10 M) and low capacity (B(max1) = 335 fmol per mg protein), while the other possessed lower affinity (K(d2) = 8.2 x 10-8 M), but a higher capacity (B(max2) = 34.4 pmol per mg proteins). Since PRL facilitates the growth of human breast cancer cell lines, these results indicate that a high proportion of human breast cancers may be PRL dependent. Routine determination of PRL receptors in biopsies of human breast cancer may permit the selection of a better treatment, since it is possible that the reduction in PRL levels could inhibit those tumors which are prolactin dependent.

AB - A micro-method is reported for the determination and characterization of prolactin (PRL) receptors in human breast cancer specimens using either intact biopsy tissue or the pellet fraction remaining from biopsies previously processed for steroid hormone receptors. Labeled human PRL is used as the ligand. The specific PRL-binding of 307 human breast cancer specimens was evaluated by this micro-method. A significant level of specific PRL-binding (3-25 fmol per mg membrane protein) was detected in 41% of US breast cancer patients and 42% of Israeli patients. Scatchard analyses, performed on pooled membrane fractions with the highest specific PRL-binding revealed one class of receptors having a dissociation constant, K(d) = 4.1 x 10-9, and specific binding capacity, B(max) = 1.3 pmol per mg protein. These preparations were exposed to 3 M MgCl2, which dissociates the endogenous-bound PRL from the hormone-receptor complex and allows the characterization of the 'total' PRL receptors. Two classes of receptors were then revealed. One class of receptors showed highly affinity (K(d1) = 8.1 x 10-10 M) and low capacity (B(max1) = 335 fmol per mg protein), while the other possessed lower affinity (K(d2) = 8.2 x 10-8 M), but a higher capacity (B(max2) = 34.4 pmol per mg proteins). Since PRL facilitates the growth of human breast cancer cell lines, these results indicate that a high proportion of human breast cancers may be PRL dependent. Routine determination of PRL receptors in biopsies of human breast cancer may permit the selection of a better treatment, since it is possible that the reduction in PRL levels could inhibit those tumors which are prolactin dependent.

UR - http://www.scopus.com/inward/record.url?scp=0023894967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023894967&partnerID=8YFLogxK

M3 - Article

C2 - 3167163

AN - SCOPUS:0023894967

VL - 42

SP - 101

EP - 109

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 2

ER -